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Objectives We determined the contribution of multiple variables to predict arrhythmic death and total mortality risk in pa-
tients with coronary disease and left ventricular dysfunction. We then constructed an algorithm to predict risk of
mortality and sudden death.
Background Many factors in addition to ejection fraction (EF) influence the prognosis of patients with coronary disease. How-
ever, there are few tools to use this information to guide clinical decisions.
Methods We evaluated the relationship between 25 variables and total mortality and arrhythmic death in 674 patients
enrolled in the MUSTT (Multicenter Unsustained Tachycardia Trial) study that did not receive antiarrhythmic ther-
apy. We then constructed risk-stratification algorithms to weight the prognostic impact of each variable on ar-
rhythmic death and total mortality risk.
Results The variables having the greatest prognostic impact in multivariable analysis were functional class, history of heart
failure, nonsustained ventricular tachycardia not related to bypass surgery, EF, age, left ventricular conduction abnor-
malities, inducible sustained ventricular tachycardia, enrollment as an inpatient, and atrial fibrillation. The model
demonstrates that patients whose only risk factor is EF30% have a predicted 2-year arrhythmic death risk5%.
Conclusions Multiple variables influence arrhythmic death and total mortality risk. Patients with EF 30% but no other risk
factor have low predicted mortality risk. Patients with EF 30% and other risk factors may have higher mortality
and a higher risk of sudden death than some patients with EF 30%. Thus, risk of sudden death in patients with
coronary disease depends on multiple variables in addition to EF. (J Am Coll Cardiol 2007;50:1150–7) © 2007
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.095m
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Audden cardiac death accounts for 450,000 deaths yearly in the
.S. (1). Furthermore, the proportion of all cardiac
See page 1158
eaths accounted for by sudden death is increasing (1). Mul-
iple clinical trials completed over the past decade have docu-
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September 18, 2007:1150–7 Prediction of Sudden DeathA number of variables have been demonstrated to identify
atients at increased risk for sudden death. Recent trials
ave focused on left ventricular ejection fraction (EF),
ecause of its demonstrated association with mortality risk
n patients with recent myocardial infarction. However, EF
acks sensitivity for prediction of sudden death; less than
0% of patients with prior infarction who die suddenly have
F 30% (2–4). Additionally, many factors besides EF
ffect the prognosis of patients with coronary artery disease,
nd several lines of evidence suggest that reduced EF is a
isk factor only when it exists in combination with other risk
actors (5,6). Given earlier studies pointing to factors other
han EF that influence prognosis after MI, the purpose of
he present study is to evaluate the relative importance of
ultiple factors and to compare their relative contribution
o risk of arrhythmic death as well as total mortality using
he MUSTT (Multicenter Unsustained Tachycardia Trial)
atabase (7,8). We then constructed a risk stratification
ool that could be used in clinical practice. We demon-
trate that use of such a model may enable more precise
isk stratification of patients with coronary disease con-
idered for ICD implantation for primary prevention of
udden death.
ethods
he MUSTT study was a randomized, controlled study
hose primary aim was to test the ability of electrophysi-
logically guided therapy to reduce the risk of arrhythmic
eath in patients with documented coronary artery disease,
eft ventricular EF 40%, and spontaneous nonsustained
entricular tachycardia (NSVT). All patients underwent a
tandardized electrophysiologic test (9). Patients with in-
ucible sustained ventricular tachycardia (VT) (monomor-
hic VT induced by 1 to 3 ventricular extrastimuli or
ustained polymorphic VT induced by 1 or 2 extrastimuli) at
he baseline electrophysiologic study were randomized
qually into 2 groups. One-half of the patients with induc-
ble ventricular tachyarrhythmias were randomized to elec-
rophysiologically guided therapy, which consisted of serial
ntiarrhythmic drug trials. Patients whose tachycardia re-
ained inducible at electrophysiologic testing after treat-
ent with at least 1 antiarrhythmic drug were advised to
ndergo defibrillator implantation. These patients who
eceived pharmacologic antiarrhythmic therapy or im-
lanted defibrillators are excluded from the present analysis.
he remaining one-half of patients with inducible tachy-
ardias were randomized to the control group and received
o antiarrhythmic therapy. Patients without either inducible
ustained monomorphic VT or sustained polymorphic VT
r fibrillation induced by 1 or 2 ventricular extrastimuli were
ollowed prospectively in a registry. The latter patients were
ot given antiarrhythmic therapy. The protocol encouraged
dministration of beta-adrenergic blocking agents and
ngiotensin-converting enzyme inhibitors to all patients. In dhe present study, we examined
he effect of multiple parameters
n the outcome of patients fol-
owed prospectively in the regis-
ry and the patients with induc-
ble tachycardia randomized to
he control group without antiar-
hythmic treatment.
tudy population. A total of
,202 patients were enrolled in
he study between 1990 and
996. One thousand four-hundred
hirty-five (65%) had no inducible
ustained VT and were followed
n the registry. At the time of
ospital discharge after enrollment in the trial, 35% of the
egistry patients were receiving beta-blockers and 66% were
eceiving angiotensin-converting enzyme inhibitors. Seven
undred sixty-seven patients (35%) had inducible sustained
T. Of these, 704 (92%) agreed to be randomized. The 63
atients who refused randomization were followed on the
ame schedule with the registry patients. Of the 704 patients
ith inducible ventricular tachyarrhythmias who agreed to
andomization, 353 were assigned to the control (nonan-
iarrhythmic therapy) arm. Although the importance of
eart failure as a risk factor for both total mortality and
udden death is clear today, when the trial was initiated in
990 this relation was not as well appreciated. We did not
ollect data regarding history of heart failure or New York
eart Association (NYHA) functional class for the first half
f the trial. As a result, complete data for all prognostic
ariables, including descriptors of heart failure, were avail-
ble for 674 patients that did not receive antiarrhythmic
herapy (Fig. 1). These patients constitute the data set for
nalysis of total mortality. The cause of death could not be
scertained with certainty in 4 patients. Thus, 670 patients
onstituted the dataset for the evaluation of arrhythmic
eath/cardiac arrest. The characteristics of these patients
id not differ significantly from those of the entire study
opulation.
We evaluated 25 baseline variables for their relationship
ith the risk of total mortality or arrhythmic death/cardiac
rrest (Table 1). The variables included demographics,
linical history, variables derived from the enrolling 12-lead
lectrocardiogram, characteristics of spontaneous NSVT,
haracteristics of a prior myocardial infarction, results of the
aseline electrophysiologic test, EF, and the extent of
oronary disease. It should be noted that the qualifying
SVT for entry into the trial had to occur within 6 months
f enrollment and be documented 4 or more days after the
ost recent myocardial infarction or revascularization pro-
edure (coronary artery bypass graft surgery [CABG] or
ercutaneous revascularization) (7,8). We have previously
emonstrated that patients whose qualifying NSVT was
Abbreviations
and Acronyms
EF  ejection fraction
ICD  implantable
cardioverter-defibrillator
IVCD  intraventricular
conduction delay
LBBB  left bundle branch
block
NSVT  nonsustained
ventricular tachycardia
VT  ventricular
tachycardiaiscovered within 10 days of CABG had significantly
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Prediction of Sudden Death September 18, 2007:1150–7ower mortality than patients who had never had CABG
r whose NSVT was discovered more than 10 days after
ABG (10). Another previous analysis demonstrated
hat patients who were enrolled while they were inpa-
ients had significantly higher mortality than those en-
olled as outpatients (11).
efinitions. ARRHYTHMIC DEATH. Witnessed instanta-
eous death, unwitnessed death in a patient who was stable
n usual state of health when last seen (most often persons
ound dead in bed in the morning), deaths due to incessant
achycardia, or sequelae of cardiac arrest. Deaths of patients
ith end-stage heart failure or cardiogenic shock were not
lassified as arrhythmic.
ARDIAC ARREST. Sudden loss of consciousness requiring
irect current countershock to restore consciousness or a
table blood pressure and rhythm.
EFT BUNDLE BRANCH BLOCK (LBBB). A QRS duration of
0.12 s; delayed onset of intrinsicoid deflection in lead 1,
5, and V6 0.05 s; broad monophasic usually notched R
aves in lead 1, V5, and V6; and rS or QS complexes in right
Figure 1 Derivation of Study Population
Flow diagram depicting patient enrollment in the MUSTT (Multicenter Unsus-
tained Tachycardia Trial) study and derivation of patients for the present study.
This figure depicts the evolution of patient enrollment in the MUSTT study, with
randomization status. For the present study, only patients that did not receive
antiarrhythmic treatment (including pharmacologic and device therapy) and in
whom complete data on heart failure status was known were included. EP 
electrophysiologic; VT  ventricular tachycardia.recordial leads. mNTRAVENTRICULAR CONDUCTION DELAY (IVCD). A QRS
uration of 0.11 s but morphology different from LBBB
r right bundle branch block.
tatistical methods. The Cox proportional hazards regres-
ion model was used to assess the relationship of each
aseline clinical variable (both individually and jointly) with
he time until the occurrence of: 1) total mortality; and
) arrhythmic death or cardiac arrest (12). For continuous
ariables, we examined the shape and strength of their
elationship with each of the 2 end points through use of a
exible model-fitting approach involving cubic spline func-
ions (cubic polynomials) (13–17). These functions were
raphically and statistically examined to assess the assump-
ion of this regression model that patient characteristics are
inearly related to the log of the hazard ratio. Where
elationships were nonlinear, their shape was characterized
ither through a transformation to achieve linearity or using
pline functions (17,18). Determining how variables should
e modeled was an important step in characterizing the
rognostic relationships and identifying which variables
ere most strongly related to the 2 end points. The ability
f the prognostic models to discriminate among patients
ith respect to their length of survival was characterized
sing a generalized c-index, an extension to survival analysis
f the c-index (area under the receiver-operating character-
stic curve) frequently used with a dichotomous end point
19). After identifying the significant predictor variables
rom the multivariable modeling process, weights for each
actor were derived from the Cox model regression coeffi-
ients to develop a prognostic score for each end point (20).
he possible values of the scores were then translated into
stimates of: 1) the probability of dying; or 2) the probability
f having an arrhythmic event within 2 years of enrollment.
he relationships between the prognostic scores and the
espective outcome probabilities were then graphically pre-
ented. Confidence intervals for the prognostic estimates
ere generated using bootstrapping techniques. Our goal in
hese analyses was to develop predictive models for each end
oint that would be relatively simple to use in clinical
ractice yet provide adequate predictive accuracy in the
ssessment of risk.
esults
he median duration of follow-up was 39 months in the
rial. Over the course of the trial, 241 of 674 patients in the
tudy population died; 130 experienced arrhythmic death or
ardiac arrest. Of 200 patients with inducible VT, 84 died
nd 53 patients experienced arrhythmic death or cardiac
rrest. In contrast, of 474 patients without inducible VT,
57 died and 77 experienced arrhythmic death or cardiac
rrest. The Kaplan-Meier 2-year total mortality rate was
2% for the entire study population. The Kaplan-Meier
-year rate of arrhythmic death or cardiac arrest was 14%.
The factors having statistically significant associations in
ultivariable analysis with the end point of total mortality
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September 18, 2007:1150–7 Prediction of Sudden Deathncluded EF, the presence of LBBB or nonspecific IVCD
these 2 variables were grouped together), NYHA func-
ional class at the time of enrollment, inducible VT, age,
rior CABG, atrial fibrillation at the time of enrollment,
nd history of heart failure (Table 2). The index of discrim-
nation (c-index) for this model was 0.78.
The factors having statistically significant associations in
ultivariable analysis with the end point of arrhythmic death/
ardiac arrest included inducible VT, history of heart failure,
atients enrolled while inhospital, EF, NSVT not discovered
ithin 10 days after CABG, LBBB, or IVCD (Table 3). Age
nd atrial fibrillation were not statistically significant predictors
f arrhythmic death/cardiac arrest. As expected, the c-index for
he end point of arrhythmic death/cardiac arrest was lower
0.70) than for total mortality, reflecting the fact that it is more
ifficult to predict 1 specific mode of death (arrhythmic) than
o predict overall mortality.
A risk stratification algorithm was then constructed and
eights assigned to each variable for the end points of total
nivariate Prognostic Relationships
Table 1 Univariate Prognostic Relationships
Variable
Patients With
Characteristic–%
Tota
Chi-Square p Va
NYHA functional class I: 37; II: 39; III: 24 51.34 0.0
Class II vs. class I
Class III vs. class I
IVCD or LBBB 26 35.75 0.0
History of heart failure 75 35.18 0.0
Ejection fraction 29 (21, 35) 34.06 0.0
Age 66 (58, 72) 12.93 0.0
Atrial fibrillation
(by ECG)
9 10.78 0.0
NSVT discovered as inpatient 75 8.06 0.0
Inducible VT 30 8.05 0.0
NSVT not discovered within
10 days after CABG
86 6.45 0.0
Prior thrombolytic therapy 21 4.69 0.0
Prior CABG 55 4.13 0.0
Prior Q-wave MI 47 3.83 0.0
History of angina 70 2.92 0.0
Number of diseased vessels
(75% stenosed)
2 (1, 3) 1.82 0.1
Prior PTCA 25 1.75 0.1
Prior polymorphic NSVT 30 1.45 0.2
RBBB 5 0.94 0.3
LVH (by ECG) 47 0.92 0.3
Years from MI to enrollment 3 (0, 10) 0.56 0.4
Prior MI 88 0.49 0.4
Longest episode of NSVT 6
beats
5 (3, 8) 0.42 0.5
Gender (male) 85 0.38 0.5
History of palpitations 26 0.02 0.8
Race (European) 84 0.02 0.8
Prior inferior MI 48 0.01 0.9
ontinuous variables are expressed as median (25th, 75th percentiles). *Hazard ratio for a 5% de
CABG coronary artery bypass graft surgery; CI confidence interval; ECG electrocardiogram;
VH left ventricular hypertrophy; MImyocardial infarction; NSVT nonsustained ventricular ta
BBB  right bundle branch block; VT  ventricular tachycardia.ortality and arrhythmic death/cardiac arrest (Tables 4 and 5).
*n individual patient’s score for mortality or arrhythmic
eath risk was computed by ascertaining which variables
haracterize that individual and summing the corresponding
oints in Tables 4 and 5. This total score was then entered
nto the x-axis of Figure 2, which shows the curves depicting
ality Arrhythmic Death or Cardiac Arrest
HR (95% CI) Chi-Square p Value HR (95% CI)
12.81 0.0017
2.43 (1.73–3.40) 1.84 (1.21–2.79)
3.67 (2.57–5.24) 2.22 (1.40–3.52)
2.20 (1.70–2.85) 9.49 0.0021 1.75 (1.23–2.51)
3.58 (2.35–5.47) 13.63 0.0002 2.55 (1.55–4.19)
1.35 (1.22–1.41)* 16.30 0.0001 1.32 (1.15–1.51)*
1.28 (1.11–1.46)† 0.21 0.6460 1.04 (0.88–1.24)†
1.84 (1.28–2.64) 0.07 0.7884 1.09 (0.60–1.96)
1.61 (1.16–2.23) 6.03 0.0141 1.76 (1.12–2.75)
1.47 (1.13–1.91) 12.73 0.0004 1.88 (1.33–2.65)
1.73 (1.13–2.63) 4.94 0.0262 1.96 (1.08–3.55)
0.68 (0.48–0.96) 2.07 0.1502 0.72 (0.45–1.13)
0.77 (0.60–0.99) 0.59 0.4431 0.88 (0.62–1.23)
0.78 (0.60–1.00) 2.10 0.1470 0.78 (0.55–1.09)
0.79 (0.61–1.04) 0.14 0.7117 0.93 (0.65–1.35)
1.10 (0.96–1.26) 4.36 0.0368 1.22 (1.01–1.47)
0.81 (0.60–1.10) 3.57 0.0589 0.66 (0.43–1.02)
1.18 (0.90–1.55) 0.54 0.4627 1.15 (0.80–1.65)
0.73 (0.39–1.38) 1.71 0.1913 0.52 (0.19–1.39)
1.13 (0.88–1.46) 2.66 0.1028 1.33 (0.95–1.86)
1.00 (0.99–1.01) 0.13 0.7232 1.00 (0.99–1.01)
0.88 (0.61–1.27) 0.22 0.6367 0.89 (0.54–1.46)
1.02 (0.97–1.06) 1.59 0.2069 1.04 (0.98–1.11)
0.90 (0.64–1.27) 0.85 0.3571 1.28 (0.76–2.16)
1.02 (0.76–1.37) 0.02 0.8971 1.03 (0.70–1.51)
1.03 (0.73–1.45) 0.01 0.9425 0.98 (0.62–1.55)
1.00 (0.78–1.29) 0.02 0.8884 1.03 (0.73–1.44)
in ejection fraction. †Hazard ratio for a 10-year increase in age.
azard ratio; IVCD nonspecific intraventricular conduction delay; LBBB left bundle branch block;
ia; NYHA New York Heart Association; PTCA percutaneous transluminal coronary angioplasty;
ultivariable Relationships With Total Mortality
Table 2 Multivariable Relationships With Total Mortality
Variable Chi-Square p Value Hazard Ratio (95% CI)
Ejection fraction 19.15 0.0001 1.26 (1.14–1.40)*
IVCD or LBBB 17.32 0.0001 1.75 (1.35–2.28)
NYHA functional class 13.55 0.0011
Class II vs. I 1.59 (1.06–2.38)
Class III vs. I 2.07 (1.35–3.17)
Inducible VT 8.52 0.0035 1.49 (1.14–1.94)
Age 8.28 0.0040 1.23 (1.07–1.41)†
Prior CABG 6.94 0.0052 0.71 (0.55–0.92)
Atrial fibrillation 6.80 0.0091 1.65 (1.13–2.40)
History of heart failure 4.02 0.0450 1.72 (1.01–2.91)l Mort
lue
001
001
001
001
003
010
045
046
111
303
422
504
877
770
857
280
328
364
538
837
186
398
889
839
847
crease
HR hHazard ratio for a 5% decrease in ejection fraction. †Hazard ratio for a 10-year increase in age.
Abbreviations as in Table 1.
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Prediction of Sudden Death September 18, 2007:1150–7he 2-year event rates for total mortality and for arrhythmic
eath/cardiac arrest for the range of possible scores for
atients in whom this model was developed. The score was
hen transposed onto the curve for the end point of interest
total mortality or arrhythmic death/cardiac arrest) and the
orresponding predicted 2-year event rate read on the y-axis
f the graph.
Examples of application of the risk-stratification algo-
ithm appear in Figures 3 to 5. In example A (Fig. 3), a
0-year-old patient whose only risk factor is an EF of 25%,
he predicted 2-year total mortality and arrhythmic death
isks are quite low (5% and 2%, respectively) even though
he EF is 30%.
In contrast, the patient depicted in example B (Fig. 4),
ho has multiple risk factors in addition to EF 30%, has
uch higher risks of both total mortality and arrhythmic
eath. Note that if this patient had inducible VT, the
rrhythmic death risk is almost as high as the total mortality
isk.
In general, the risks of both arrhythmic death and total
ortality are lower for patients whose EF is 30%. How-
ver, example C (Fig. 5) demonstrates that some patients
hose EF is 30% may be at similar or higher risk than
ertain patients whose EF is 30%. For example, in this
ase of a hypothetical patient with an EF of 35%, the total
ultivariable Relationships Withrrhythmic Death or Cardiac Arrest
Table 3 Multivariable Relationships WithArrhythmic Death or Cardiac Arrest
Variable Chi-Square p Value
Hazard Ratio
(95% CI)
Inducible VT 12.55 0.0004 1.89 (1.33–2.69)
History of heart failure 6.84 0.0089 1.99 (1.19–3.33)
Patient enrolled as inpatient 6.80 0.0091 1.88 (1.17–3.02)
Ejection fraction 6.35 0.0118 1.19 (1.07–1.37)*
NSVT not discovered within
10 days after CABG
4.04 0.0443 1.86 (1.02–3.40)
IVCD or LBBB 3.94 0.0473 1.46 (1.01–2.11)
Hazard ratio for a 5% decrease in ejection fraction.
Abbreviations as in Table 1.
alculation of Total Mortality Score
Table 4 Calculation of Total Mortality Score
EF 20 20
For values of EF between 20 and 40, add 1 point for each EF point 40
EF  40 0
IVCD or LBBB 12
NYHA functional class
Class III 14
Class II 7
Inducible VT 8
Age 80 yrs 15
For each year between 50 and 80, add 0.5 point
Age 50 yrs 0
No prior CABG 7
History of atrial fibrillation 11
History of congestive heart failure 13aF  ejection fraction; other abbreviations as in Table 1.ortality and arrhythmic death risks are virtually identical
o those of the patient in the first part of example B (Fig. 4)
hose EF was 25%.
The execution and implications of this approach to risk
tratification are influenced by the relative prevalence of
arious risk factors. Patients having an EF 30% had a
igher prevalence of associated risk factors, such as electro-
ardiographic conduction abnormalities and symptomatic
eart failure (Table 6). However, Table 6 demonstrates that
significant minority (25%) of patients whose EF was 30%
r less did not have these additional risk factors.
iscussion
his analysis of patients enrolled in the MUSTT study who
eceived neither pharmacologic antiarrhythmic therapy nor
n implanted defibrillator demonstrates that multiple factors
nfluence mortality of patients with chronic coronary artery
isease. In addition, this study illustrates that much prog-
ostic information can be gained from easily determined
istorical factors. We have shown that although EF is an
mportant risk predictor, in this study population several
ther variables carry similar prognostic significance. Fur-
hermore, the present study demonstrates the potential
anger of focusing efforts to reduce risk of sudden death
nly on patients with EF 30%. We demonstrate that
epending on the presence of other risk factors, patients
ith EF 30% to 40% may have total mortality and sudden
eath risks that exceed those of some patients with EF
30%.
The algorithm we developed does not represent the
ultimate” risk-stratification tool. Rather, it serves as an
xample of the potential utility of this approach to risk
tratification. The algorithm developed in this study, or a
imilar one, could be applied easily to risk-stratify patients
aving the characteristics of those enrolled in the MUSTT
tudy (and should only be applied to such patients). Of note,
xcept for the electrophysiologic study, the variables in these
rediction models are noninvasive and easily determined in
he office setting without any special equipment.
The variables that were associated with highest risk for total
ortality as well as arrhythmic death are not surprising. The
alculation of Arrhythmiceath/Cardiac A rest Score
Table 5 Calculation of ArrhythmicDeath/Cardiac Arrest Score
Inducible VT 17
History of CHF 19
Patient enrolled as inpatient 17
EF 20 20
For values of EF between 20 and 40, add one point for each
EF point 40
EF  40 0
NSVT not discovered within 10 days after CABG 17
IVCD or LBBB 10
bbreviations as in Tables 1 and 4.ssociation between inpatient (vs. outpatient) status and higher
m
c
a
i
m
c
d
w
a
T
t
t
t
c
b
M
w
i
s
m
s
b
M
t
c
M
a
a
e
o
c
s
(
n
i
e
p
h
1155JACC Vol. 50, No. 12, 2007 Buxton et al.
September 18, 2007:1150–7 Prediction of Sudden Deathortality risk was demonstrated for patients experiencing
ardiac arrest in the AVID (Antiarrhythmics Versus Implant-
ble Defibrillators) trial (21). Older age would be expected to
ncrease total mortality risk but not necessarily risk for arrhyth-
ic death. Conversely, the independent prognostic signifi-
ance of inducible sustained VT for prediction of arrhythmic
eath has been demonstrated and is expected (22).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 10 20 30 4
T
w
o
-Y
ea
r  
E
ve
n
t 
R
at
e
Score 0 5 10 15 20 25 30 35 40 45
TM 2 3 3 4 5 7 9 11 14 17
AD/CA 1 2 2 2 3 3 4 4 5 6
Figure 2 Relationship of Multivariable Risk Scores to 2-Year Ev
Graphical representation of risk stratification algorithm to predict 2-year event rate
The table beneath the graph relates numerical risk scores for total mortality (TM)
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Example A
A 60-year-old patient with prior CABG, NSVT only documented within 10 days after CABG,
EF 25%, narrow QRS complex, no inducible sustained VT, no current or past heart failure 
Parameter Arrhythmic Death Score Total Mortality Score
Age = 60 years 5
EF = 25%    15      15 
Total score    15      20 
Figure 3 Example of a Low-Risk Patient With EF <30%
Graphical representation of the hypothetical patient described in the text as
example A. This patient’s only risk factors are reduced ejection fraction (EF)
and age 60 years. CABG  coronary artery bypass graft; NSVT  nonsustained
ventricular tachycardia; other abbreviations as in Figure 1.LApplication of this model demonstrates that patients
hose only risk factor is having an EF of 30% or less have
predicted 2-year total mortality risk of approximately 5%.
his rate is considerably lower than the observed 2-year
otal mortality rate of 22% for control patients enrolled in
he MADIT (Multicenter Automatic Defibrillator Implan-
ation Trial)-II study (23). This difference in risk is espe-
ially striking when one considers 2 additional differences
etween these 2 studies. First, patients enrolled in the
USTT study were required to have nonsustained VT,
hich is associated with higher mortality after myocardial
nfarction (9), whereas patients enrolled in the MADIT-II
tudy were not required to have nonsustained VT docu-
ented. Second, only one-third of patients in the MUSTT
tudy who did not have inducible sustained VT received
eta-blocking agents versus 70% of patients enrolled in the
ADIT-II study (because MADIT-II was conducted in
he late 1990s, when beta-blockade was more widely ac-
epted in this patient population). It seems likely that if the
USTT population were treated with beta-blocking agents
t rates consistent with current practice, the total mortality
nd arrhythmic death/cardiac arrest rates would have been
ven lower than those observed.
We believe the explanation for the much higher mortality
bserved in the control arm of the MADIT-II study
ompared with that of patients enrolled in the MUSTT
tudy matching the entry requirements of the MADIT-II
chronic coronary artery disease and EF 30%, but having
o other variables from the current model associated with
ncreased mortality) lies in the characteristics of patients
nrolled in the MADIT-II study. Sixty-one percent of
atients enrolled in the MADIT-II study had symptomatic
eart failure (NYHA functional class 2), and 44% had
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Prediction of Sudden Death September 18, 2007:1150–7atient characteristics on the observed 2-year mortality of
2% in the MADIT-II control patients is substantiated by
omparison of this event rate with that observed in the
CD-HeFT (Sudden Cardiac Death in Heart Failure Trial)
24). In that trial, which required patients to have symp-
omatic heart failure as well as EF 35%, patients with
oronary disease as the cause of heart failure randomized to
lacebo had a 2-year mortality of 18%, similar to the
ortality observed in MADIT-II patients. Note that 41%
f SCD-HeFT patients with ischemic disease had the
dditional risk factor of QRS duration 120 ms, similar to
he MADIT-II study population.
tudy limitations. This model requires validation by a
rospective trial. The use of this model must be restricted to
atients having documented coronary artery disease, left
entricular EF of 40% or less, and asymptomatic spontane-
us nonsustained VT. The application of this model is also
ependent on performing an electrophysiologic study to
Example B
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A 60-year-old patient with prior CABG, EF 30%, history of heart failure, currently NYHA class 2, 
with LBBB, no inducible sustained VT, NSVT documented and occurred remote (>10) days after
CABG.
Parameter Arrhythmic Death Score Total Mortality Score
Age = 60 years 5
EF = 30%    10      10
History of heart failure   19      13
NYHA Class 2 7
LBBB     10      12
NSVT not within 10 d of CABG 17
Total score    56      47 
If this patient had inducible sustained VT at EP testing:
Total score    73      55 
Figure 4 Example of a High-Risk Patient With EF <30%
Graphical representation of the hypothetical patient described in the text as
example B. Like the patient described in example A (Fig. 3), this patient is 60
years old with reduced EF. However, this patient has additional risk factors of
symptomatic heart failure and left bundle branch block (LBBB). Predicted risk
for both total mortality and arrhythmic death is much higher than that of the
patient without heart failure symptoms or left bundle branch block. NYHA 
New York Heart Association; other abbreviations as in Figures 1 and 3.etermine if sustained VT is inducible. This algorithm Ahould not be applied to patients with ventricular dysfunc-
ion due to noncoronary disease. It is also possible that use
f other noninvasive tests, such as measurement of T-wave
lternans or the signal-averaged electrocardiogram, might
mprove the performance of this model. This study should
ot be construed to be a test of defibrillator efficacy.
owever, the intelligent use of defibrillators demands an
nderstanding of the risk of both sudden and nonsudden
eath risks tailored to individual patients. This model
emonstrates both the complexity and the feasibility of such
isk modeling.
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Example C. 
A 65-year-old person has never undergone CABG, EF 35%, history of heart failure, currently 
NYHA class 2, with inducible VT, narrow QRS complex, documented NSVT.
Parameter Arrhythmic Death Score Total Mortality Score
Age = 65 years 8
No prior CABG 7
EF = 35% 5 5
History of heart failure   19      13
NYHA Class 2 7
Inducible VT    17 8
NSVT not within 10 d of CABG 17
Total score    58      48 
Figure 5 Example of a High-Risk Patient With EF >30%
Graphical representation of the hypothetical patient described in the text as
example C. This patient’s ejection fraction (EF) is greater than 30%, but
because symptomatic heart failure and inducible VT are present, the risks for
both total mortality and arrhythmic death are comparable to those of some
patients with much lower EF. Abbreviations as in Figures 3 and 4.
revalence of Additional Riskactors in Relation to Ejection Fraction
Table 6 Prevalence of Additional RiskFactors in Relation to Ejection Fraction
EF <30%
(n  433)
EF >30%
(n  241)
No other mortality risk factors (age excluded) 16 (4%) 27 (11%)
No IVCD or LBBB or NYHA functional class II
or III
109 (25%) 99 (41%)
No IVCD or LBBB or NYHA functional class II
or III, but randomizable VT
37 (9%) 28 (12%)bbreviations as in Table 1.
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n summary, it is accepted that the ICD is the best therapy
urrently available to prevent sudden death in high-risk
atients. However, recent clinical trials, which demon-
trated the spectrum of efficacy of the ICD, were not
esigned to evaluate optimal methods for risk stratification
f myocardial infarction survivors. Given the expense and
isks of ICDs, it is logical to search for methods of using this
echnology in the most cost-effective manner. The present
nalysis presents one approach to solving this problem. Our
odel demonstrates that multiple variables in addition to
eft ventricular dysfunction (reflected by EF) influence
ortality of patients with coronary artery disease. We have
emonstrated that consideration of multiple risk factors has
he potential to provide more accurate prediction for risk of
udden death as well as total mortality. As a result, the
odel identifies a population of patients that meets current
uidelines for prophylactic ICD implantation in patients
ith coronary disease but is unlikely to derive a significant
mprovement in 2-year survival with the ICD.
eprint requests and correspondence: Dr. Alfred E. Buxton,
ardiology Division, Brown Medical School, 2 Dudley Street, Suite
60, Providence, Rhode Island 02905. E-mail: alfred_buxton@
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